Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
BLSM · NASDAQ · Pharmaceutical Preparations · No 10-K yet
Blossomhill Therapeutics (BLSM) · oqro.io/stocks/BLSM · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$14.02−0.82 (−5.53%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
No open-market purchase by an insider of Blossomhill Therapeutics is on record in SEC filings since 2006.
No open-market sale by an insider of Blossomhill Therapeutics (BLSM) was filed with the SEC in the last 90 days.
No trade in Blossomhill Therapeutics (BLSM) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−12.4% (−$1.98) from Aug 7, 2026 to Nov 13, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $16.00 on Aug 7, 2026 to $14.02 on Nov 13, 2026 (−12.4%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in San Diego, CA. Listed, but no annual report (10-K) filed yet under this SEC registration.
Last 12 months
Not enough history
Market value
$446M
Short interest: 590K shares sold short (1.9% of shares outstanding), +21.7% vs the previous count, 4.7 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
—
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $95.4M, at Jun 30, 2026
Net income, last 12 months
—
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 12, 2026.
Nothing reported yet
New filings show up here as soon as they are processed.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
1 certified in FY2026 Q3, vs 0 a year earlier. 1 position in total, median offered wage $101K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Fails to deliver: 52K shares (about $1.34M) were not delivered on time for settlement on Sep 21, 2026. SEC fails-to-deliver data.
Fails to deliver have many causes, including processing delays, and are often resolved within days.
Against the S&P 500 over the year
Since Aug 7, 2026, BLSM is down 12.4% and the index fund is down 2.4%: 10 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much BLSM moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
0 active phase 3 trials and 1 active phase 2 trial led by this company, mostly in nsclc (advanced non-small cell lung cancer). The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
On the public record for Blossomhill Therapeutics over the 12 months to Nov 14, 2026: 1 clinical trial.